New drug combo aims to stall bone sarcoma in phase 2 trial
NCT ID NCT07619950
First seen Jun 06, 2026 · Last updated Jun 19, 2026 · Updated 2 times
Summary
This study tests whether combining two drugs, lenvatinib and everolimus, works better than everolimus alone for people with advanced bone sarcoma (osteosarcoma, Ewing sarcoma, or chondrosarcoma) that has progressed after standard treatment. About 94 adults aged 19 to 79 will be randomly assigned to one of the two treatment groups. The main goal is to see if the combination can stop the cancer from growing for at least 24 weeks. Researchers will also look for biomarkers by taking blood and tissue samples during the study.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOSARCOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.